1. Li AP, 2001, Screening for human ADME/Tox drug properties in drug discovery. Drug Discov Today, 6: 357–366. https://doi.org/10.1016/s1359-6446(01)01712-3 

2. Wishart DS, 2016, Emerging applications of metabolomics in drug discovery and precision medicine. Nat Rev Drug Discov, 15: 473–484. https://doi.org/10.1038/nrd.2016.32 

3. Hingorani AD, Kuan V, Finan C, et al., 2019, Improving the odds of drug development success through human genomics: Modelling study. Sci Rep, 9: 18911. https://doi.org/10.1038/s41598-019-54849-w 

4. Serras AS, Rodrigues JS, Cipriano M, et al., 2021, A critical perspective on 3D liver models for drug metabolism and toxicology studies. Front Cell Dev Biol, 9: 626805. https://doi.org/10.3389/fcell.2021.626805 

5. Park Y, Huh KM, Kang SW, 2021, Applications of biomaterials in 3D cell culture and contributions of 3D cell culture to drug development and basic biomedical research. Int J Mol Sci, 22: 2491. https://doi.org/10.3390/ijms22052491
 
6. Ma C, Peng Y, Li H, et al., 2021, Organ-on-a-chip: A new paradigm for drug development. Trends Pharmacol Sci, 42: 119–133. https://doi.org/10.1016/j.tips.2020.11.009
 
7. Saltsman JA, Hammond WJ, Narayan NJ, et al., 2020, A human organoid model of aggressive hepatoblastoma for disease modeling and drug testing. Cancers (Basel), 12: 2668. https://doi.org/10.3390/cancers12092668 

8. Takahashi T, 2019, Organoids for drug discovery and personalized medicine. Annu Rev Pharmacol Toxicol, 59: 447–462. https://doi.org/10.1146/annurev-pharmtox-010818-021108 

9. Devarasetty M, Mazzocchi AR, Skardal A, 2018, Applications of bioengineered 3D tissue and tumor organoids in drug development and precision medicine: Current and future. BioDrugs, 32: 53–68. https://doi.org/10.1007/s40259-017-0258-x 

10. Peng W, Datta P, Ayan B, et al., 2017, 3D bioprinting for drug discovery and development in pharmaceutics. Acta Biomater, 57: 26–46. https://doi.org/10.1016/j.actbio.2017.05.025 

11. Sun D, Gao W, Hu H, et al., 2022, Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B, 12: 3049–3062. https://doi.org/10.1016/j.apsb.2022.02.002 

12. Smith DA, Beaumont K, Maurer TS, et al., 2019, Clearance in drug design. J Med Chem, 62: 2245–2255. https://doi.org/10.1021/acs.jmedchem.8b01263 

13. Phua J, Lee KH, 2008, Liver support devices. Curr Opin Crit Care, 14: 208–215. https://doi.org/10.1097/MCC.0b013e3282f70057 

14. Zhang X, Jiang T, Chen D, et al., 2020, Three-dimensional liver models: State of the art and their application for hepatotoxicity evaluation. Crit Rev Toxicol, 50: 279–309. https://doi.org/10.1080/10408444.2020.1756219
 
15. Roden M, 2016, The liver in focus. Diabetologia, 59: 1095–1097. https://doi.org/10.1007/s00125-016-3911-x 

16. Lorente S, Hautefeuille M, Sanchez-Cedillo A, 2020, The liver, a functionalized vascular structure. Sci Rep, 10: 16194. https://doi.org/10.1038/s41598-020-73208-8 

17. Shin D, Monga SP, 2013, Cellular and molecular basis of liver development. Compr Physiol, 3(2): 799–815. https://doi.org/10.1002/cphy.c120022 

18. Stockert RJ, Wolkoff AW, 2001, Cellular and molecular biology of the liver. Curr Opin Gastroenterol, 17: 205–210. https://doi.org/10.1097/00001574-200105000-00003
 
19. Popper H, 1956, Correlation of liver structure and function. Q Bull Northwest Univ Med Sch, 30: 325–330. http://www.ncbi.nlm.nih.gov/pubmed/13408428
 
20. Michalopoulos GK, Bhushan B, 2021, Liver regeneration: biological and pathological mechanisms and implications. Nat Rev Gastroenterol Hepatol, 18: 40–55. https://doi.org/10.1038/s41575-020-0342-4 

21. Poyck PP, Hoekstra R, Chhatta A, et al., 2007, Time-related analysis of metabolic liver functions, cellular morphology, and gene expression of hepatocytes cultured in the bioartificial liver of the academic medical center in Amsterdam (AMC-BAL). Tissue Eng, 13: 1235–1246. https://doi.org/10.1089/ten.2006.0343 

22. Pahlavan PS, Feldmann RE Jr., Zavos C, et al., 2006, Prometheus’ challenge: molecular, cellular and systemic aspects of liver regeneration. J Surg Res, 134: 238–251. https://doi.org/10.1016/j.jss.2005.12.011 

23. Vellonen KS, Malinen M, Mannermaa E, et al., 2014, A critical assessment of in vitro tissue models for ADME and drug delivery. J Control Release, 190: 94–114. https://doi.org/10.1016/j.jconrel.2014.06.044 

24. Madden LR, Nguyen TV, Garcia-Mojica S, et al., 2018, Bioprinted 3D primary human intestinal tissues model aspects of native physiology and ADME/Tox functions. iScience, 2: 156–167. https://doi.org/10.1016/j.isci.2018.03.015 

25. Faber KN, Muller M, Jansen PL, 2003, Drug transport proteins in the liver. Adv Drug Deliv Rev, 55: 107–124. https://doi.org/10.1016/s0169-409x(02)00173-4 

26. Sawant-Basak A, Obach RS, 2018, Emerging models of drug metabolism, transporters, and toxicity. Drug Metab Dispos, 46: 1556–1561. https://doi.org/10.1124/dmd.118.084293 

27. Jetter A, Kullak-Ublick GA, 2020, Drugs and hepatic transporters: A review. Pharmacol Res, 154: 104234. https://doi.org/10.1016/j.phrs.2019.04.018 

28. Gholam PM, 2020, A focus on drug-induced liver injury. Clin Liver Dis, 24: xiii–xiv. https://doi.org/10.1016/j.cld.2019.10.001 

29. Beckwitt CH, Clark AM, Wheeler S, et al., 2018, Liver “organ on a chip”. Exp Cell Res, 363: 15–25. https://doi.org/10.1016/j.yexcr.2017.12.023 

30. Shimoda H, Yagi H, Higashi H, et al., 2019, Decellularized liver scaffolds promote liver regeneration after partial hepatectomy. Sci Rep, 9: 12543. https://doi.org/10.1038/s41598-019-48948-x 

31. Chen Y, Geerts S, Jaramillo M, et al., 2018, Preparation of decellularized liver scaffolds and recellularized liver grafts. Methods Mol Biol, 1577: 255–270. https://doi.org/10.1007/7651_2017_56 

32. Vatakuti S, Olinga P, Pennings JL, et al., 2017, Validation of precision-cut liver slices to study drug-induced cholestasis: A transcriptomics approach. Arch Toxicol, 91: 1401–1412. https://doi.org/10.1007/s00204-016-1778-8
 
33. Othman A, Ehnert S, Dropmann A, et al., 2020, Precision-cut liver slices as an alternative method for long-term hepatotoxicity studies. Arch Toxicol, 94: 2889–2891. https://doi.org/10.1007/s00204-020-02861-9
 
34. Steimberg N, Bertero A, Chiono V, et al., 2020, iPS, organoids and 3D models as advanced tools for in vitro toxicology. ALTEX, 37: 136–140. https://doi.org/10.14573/altex.1911071 

35. Torok G, Erdei Z, Lilienberg J, et al., 2020, The importance of transporters and cell polarization for the evaluation of human stem cell-derived hepatic cells. PLoS One, 15: e0227751. https://doi.org/10.1371/journal.pone.0227751

36. Nguyen DG, Funk J, Robbins JB, et al., 2016, Bioprinted 3D primary liver tissues allow assessment of organ-level response to clinical drug induced toxicity in vitro. PLoS One, 11: e0158674. https://doi.org/10.1371/journal.pone.0158674 

37. Bell CC, Hendriks DF, Moro SM, et al., 2016, Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease. Sci Rep, 6: 25187. https://doi.org/10.1038/srep25187 

38. Kanebratt KP, Janefeldt A, Vilen L, et al., 2021, Primary human hepatocyte spheroid model as a 3D in vitro platform for metabolism studies. J Pharm Sci, 110: 422–431. https://doi.org/10.1016/j.xphs.2020.10.043 

39. Li F, Cao L, Parikh S, et al., 2020, Three-dimensional spheroids with primary human liver cells and differential roles of kupffer cells in drug-induced liver injury. J Pharm Sci, 109: 1912–1923. https://doi.org/10.1016/j.xphs.2020.02.021
 
40. Ware BR, Liu JS, Monckton CP, et al., 2021, Micropatterned coculture with 3T3-J2 fibroblasts enhances hepatic functions and drug screening utility of heparg cells. Toxicol Sci, 181: 90–104. https://doi.org/10.1093/toxsci/kfab018 

41. Trask OJ Jr., Moore A, LeCluyse EL, 2014, A micropatterned hepatocyte coculture model for assessment of liver toxicity using high-content imaging analysis. Assay Drug Dev Technol, 12: 16–27. https://doi.org/10.1089/adt.2013.525 

42. Liu Y, Li H, Yan S, et al., 2014, Hepatocyte cocultures with endothelial cells and fibroblasts on micropatterned fibrous mats to promote liver-specific functions and capillary formation capabilities. Biomacromolecules, 15: 1044–1054. https://doi.org/10.1021/bm401926k 

43. Khetani SR, Kanchagar C, Ukairo O, et al., 2013, Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. Toxicol Sci, 132: 107–117. https://doi.org/10.1093/toxsci/kfs326
 
44. Choi YJ, Kim H, Kim JW, et al., 2018, Hepatic esterase activity is increased in hepatocyte-like cells derived from human embryonic stem cells using a 3D culture system. Biotechnol Lett, 40: 755–763. https://doi.org/10.1007/s10529-018-2528-1 

45. Sharma VR, Shrivastava A, Gallet B, et al., 2019, Canalicular domain structure and function in matrix-free hepatic spheroids. Biomater Sci, 8: 485–496. https://doi.org/10.1039/c9bm01143a 

46. Elje E, Mariussen E, Moriones OH, et al., 2020, Hepato(Geno) toxicity assessment of nanoparticles in a HepG2 liver spheroid model. Nanomaterials (Basel), 10: 545. https://doi.org/10.3390/nano10030545
 
47. Flores-Torres S, Peza-Chavez O, Kuasne H, et al., 2021, Alginate-gelatin-matrigel hydrogels enable the development and multigenerational passaging of patient-derived 3D bioprinted cancer spheroid models. Biofabrication 13: 025001. https://doi.org/10.1088/1758-5090/abdb87 

48. Gunti S, Hoke AT, Vu KP, et al., 2021, Organoid and spheroid tumor models: Techniques and applications. Cancers (Basel), 13: 874. https://doi.org/10.3390/cancers13040874 

49. Kim SJ, Kim EM, Yamamoto M, et al., 2020, Engineering multi-cellular spheroids for tissue engineering and regenerative medicine. Adv Healthc Mater, 9: e2000608. https://doi.org/10.1002/adhm.202000608 

50. Proctor WR, Foster AJ, Vogt J, et al., 2017, Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury. Arch Toxicol, 91: 2849–2863. https://doi.org/10.1007/s00204-017-2002-1 

51. Wang Z, Luo X, Anene-Nzelu C, et al., 2015, HepaRG culture in tethered spheroids as an in vitro three-dimensional model for drug safety screening. J Appl Toxicol, 35: 909–917. https://doi.org/10.1002/jat.3090 

52. Hendriks DF, Vorrink SU, Smutny T, et al., 2020, Clinically relevant cytochrome P450 3A4 induction mechanisms and drug screening in three-dimensional spheroid cultures of primary human hepatocytes. Clin Pharmacol Ther, 108: 844–855. https://doi.org/10.1002/cpt.1860 

53. Ingelman-Sundberg M, Lauschke VM, 2021, 3D human liver spheroids for translational pharmacology and toxicology. Basic Clin Pharmacol Toxicol, 130: 5–15. https://doi.org/10.1111/bcpt.13587 

54. Sant S, Johnston PA, 2017, The production of 3D tumor spheroids for cancer drug discovery. Drug Discov Today Technol, 23: 27–36. https://doi.org/10.1016/j.ddtec.2017.03.002 

55. Hurrell T, Ellero AA, Masso ZF, et al., 2018, Characterization and reproducibility of HepG2 hanging drop spheroids toxicology in vitro. Toxicol In Vitro, 50: 86–94. https://doi.org/10.1016/j.tiv.2018.02.013
 
56. Pinto B, Henriques AC, Silva PMA, et al., 2020, Three-dimensional spheroids as in vitro preclinical models for cancer research. Pharmaceutics, 12: 1186. https://doi.org/10.3390/pharmaceutics12121186 

57. Penzes A, Abdelwahab EM, Rapp J, et al., 2017, Toxicology studies of primycin-sulphate using a three-dimensional (3D) in vitro human liver aggregate model. Toxicol Lett, 281: 44–52. https://doi.org/10.1016/j.toxlet.2017.09.005 

58. Lancaster MA, Knoblich JA, 2014, Organogenesis in a dish: Modeling development and disease using organoid technologies. Science, 345: 1247125. https://doi.org/10.1126/science.1247125 

59. Simian M, Bissell MJ, 2017, Organoids: A historical perspective of thinking in three dimensions. J Cell Biol, 216: 31–40. https://doi.org/10.1083/jcb.201610056 

60. Fatehullah A, Tan SH, Barker N, 2016, Organoids as an in vitro model of human development and disease. Nat Cell Biol, 18: 246–254. https://doi.org/10.1038/ncb3312 

61. Skottvoll FS, Hansen FA, Harrison S, et al., 2021, Electromembrane extraction and mass spectrometry for liver organoid drug metabolism studies. Anal Chem, 93: 3576–3585. https://doi.org/10.1021/acs.analchem.0c05082
 
62. Nuciforo S, Heim MH, 2021, Organoids to model liver disease. JHEP Rep, 3: 100198. https://doi.org/10.1016/j.jhepr.2020.100198 

63. Zhu M, Huang Y, Bian S, et al., 2020, Organoid: Current implications and pharmaceutical applications in liver diseases. Curr Mol Pharmacol, 14: 498–508. https://doi.org/10.2174/1874467213666201217115854 

64. Messina A, Luce E, Hussein M, et al., 2020, Pluripotent-stem-cell-derived hepatic cells: Hepatocytes and organoids for liver therapy and regeneration. Cells, 9: 420. https://doi.org/10.3390/cells9020420 

65. Kim J, Koo BK, Knoblich JA, 2020, Human organoids: model systems for human biology and medicine. Nat Rev Mol Cell Biol, 21: 571–584. https://doi.org/10.1038/s41580-020-0259-3 

66. Driehuis E, Kretzschmar K, Clevers H, 2020, Establishment of patient-derived cancer organoids for drug-screening applications. Nat Protoc, 15: 3380–3409. https://doi.org/10.1038/s41596-020-0379-4
 
67. Corro C, Novellasdemunt L, Li VS, 2020, A brief history of organoids. Am J Physiol Cell Physiol, 319: C151–C165. https://doi.org/10.1152/ajpcell.00120.2020
 
68. Prior N, Inacio P, Huch M, 2019, Liver organoids: from basic research to therapeutic applications. Gut, 68: 2228–2237. https://doi.org/10.1136/gutjnl-2019-319256 

69. Mun SJ, Ryu JS, Lee MO, et al., 2019, Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids. J Hepatol, 71: 970–985. https://doi.org/10.1016/j.jhep.2019.06.030 

70. Augustyniak J, Bertero A, Coccini T, et al., 2019, Organoids are promising tools for species-specific in vitro toxicological studies. J Appl Toxicol, 39: 1610–1622. https://doi.org/10.1002/jat.3815 

71. Akbari S, Arslan N, Senturk S, et al., 2019, Next-generation liver medicine using organoid models. Front Cell Dev Biol, 7: 345. https://doi.org/10.3389/fcell.2019.00345
 
72. Nuciforo S, Fofana I, Matter MS, et al., 2018, Organoid models of human liver cancers derived from tumor needle biopsies. Cell Rep, 24: 1363–1376. https://doi.org/10.1016/j.celrep.2018.07.001 

73. Hu H, Gehart H, Artegiani B, et al., 2018, Long-term expansion of functional mouse and human hepatocytes as 3D organoids. Cell, 175: 1591–1606 e1519. https://doi.org/10.1016/j.cell.2018.11.013
 
74. Artegiani B, Clevers H, 2018, Use and application of 3D-organoid technology. Hum Mol Genet, 27: R99–R107. https://doi.org/10.1093/hmg/ddy187
 
75. Schneeberger K, Spee B, Costa P, et al., 2017, Converging biofabrication and organoid technologies: the next frontier in hepatic and intestinal tissue engineering? Biofabrication, 9: 013001. https://doi.org/10.1088/1758-5090/aa6121 

76. Dutta D, Heo I, Clevers H, 2017, Disease modeling in stem cell-derived 3D organoid systems. Trends Mol Med, 23: 393–410. https://doi.org/10.1016/j.molmed.2017.02.007 

77. Leite SB, Roosens T, El Taghdouini A, et al., 2016, Novel human hepatic organoid model enables testing of drug-induced liver fibrosis in vitro. Biomaterials, 78: 1–10. https://doi.org/10.1016/j.biomaterials.2015.11.026 

78. Gilazieva Z, Ponomarev A, Rutland C, et al., 2020, Promising applications of tumor spheroids and organoids for personalized medicine. Cancers (Basel), 12: 2727. https://doi.org/10.3390/cancers12102727 

79. Chen EP, Toksoy Z, Davis BA, et al., 2021, 3D Bioprinting of vascularized tissues for in vitro and in vivo applications. Front Bioeng Biotechnol, 9: 664188. https://doi.org/10.3389/fbioe.2021.664188 

80. Lee JM, Sing SL, Zhou M, et al., 2018, 3D bioprinting processes: A perspective on classification and terminology. Int J Bioprint, 4: 151. https://doi.org/10.18063/IJB.v4i2.151 

81. Hagenbuchner J, Nothdurfter D, Ausserlechner MJ, 2021, 3D bioprinting: Novel approaches for engineering complex human tissue equivalents and drug testing. Essays Biochem, 65: 417–427. https://doi.org/10.1042/EBC20200153
 
82. Nguyen DG, Pentoney SL Jr., 2017, Bioprinted three dimensional human tissues for toxicology and disease modeling. Drug Discov Today Technol, 23: 37–44. https://doi.org/10.1016/j.ddtec.2017.03.001 

83. Kryou C, Leva V, Chatzipetrou M, et al., 2019, Bioprinting for liver transplantation. Bioengineering (Basel), 6: 95. https://doi.org/10.3390/bioengineering6040095 

84. Tasoglu S, Demirci U, 2013, Bioprinting for stem cell research. Trends Biotechnol, 31: 10–19. https://doi.org/10.1016/j.tibtech.2012.10.005 

85. Agarwal T, Banerjee D, Konwarh R, et al., 2021, Recent advances in bioprinting technologies for engineering hepatic tissue. Mater Sci Eng C Mater Biol Appl, 123: 112013. https://doi.org/10.1016/j.msec.2021.112013 

86. Vurat MT, Ergun C, Elcin AE, et al., 2020, 3D bioprinting of tissue models with customized bioinks. Adv Exp Med Biol, 1249: 67–84. https://doi.org/10.1007/978-981-15-3258-0_5 

87. Tandon R, Froghi S, 2020, Artificial liver support systems. J Gastroenterol Hepatol, 36: 1164–1179. https://doi.org/10.1111/jgh.15255 

88. Matai I, Kaur G, Seyedsalehi A, et al., 2020, Progress in 3D bioprinting technology for tissue/organ regenerative engineering. Biomaterials, 226: 119536. https://doi.org/10.1016/j.biomaterials.2019.119536 

89. Ma L, Wu Y, Li Y, et al., 2020, Current advances on 3D-bioprinted liver tissue models. Adv Healthc Mater, 9: e2001517. https://doi.org/10.1002/adhm.202001517 

90. Wang X, 2019, Advanced polymers for three-dimensional (3D) organ bioprinting. Micromachines (Basel), 10: 814. https://doi.org/10.3390/mi10120814 

91. He YT, Qi YN, Zhang BQ, et al., 2019, Bioartificial liver support systems for acute liver failure: A systematic review and meta-analysis of the clinical and preclinical literature. World J Gastroenterol, 25: 3634–3648. https://doi.org/10.3748/wjg.v25.i27.3634 

92. Chamuleau RA, 2009, Future of bioartificial liver support. World J Gastrointest Surg, 1: 21–25. https://doi.org/10.4240/wjgs.v1.i1.21 

93. Lelievre SA, Kwok T, Chittiboyina S, 2017, Architecture in 3D cell culture: An essential feature for in vitro toxicology. Toxicol In Vitro, 45: 287–295. https://doi.org/10.1016/j.tiv.2017.03.012 

94. Hong N, Yang GH, Lee J, et al., 2018, 3D bioprinting and its in vivo applications. J Biomed Mater Res B Appl Biomater, 106: 444–459. https://doi.org/10.1002/jbm.b.33826 

95. Yu J, Park SA, Kim WD, et al., 2020, Current advances in 3D bioprinting technology and its applications for tissue engineering. Polymers (Basel), 12: 2958. https://doi.org/10.3390/polym12122958 

96. Vernerey FJ, Sridhar SL, Muralidharan A, et al., 2021, Mechanics of 3D cell-hydrogel interactions: Experiments, models, and mechanisms. Chem Rev, 121: 11085–11148. https://doi.org/10.1021/acs.chemrev.1c00046
 
97. Hauser PV, Chang HM, Nishikawa M, et al., 2021, Bioprinting scaffolds for vascular tissues and tissue vascularization. Bioengineering (Basel), 8: 178. https://doi.org/10.3390/bioengineering8110178 

98. Panwar A, Tan LP, 2016, Current status of bioinks for micro-extrusion-based 3D bioprinting. Molecules, 21: 685. https://doi.org/10.3390/molecules21060685 

99. Zhuang P, Ng WL, An J, et al., 2019, Layer-by-layer ultraviolet assisted extrusion-based (UAE) bioprinting of hydrogel constructs with high aspect ratio for soft tissue engineering applications. PLoS One, 14: e0216776. https://doi.org/10.1371/journal.pone.0216776 

100. Li X, Liu B, Pei B, et al., 2020, Inkjet bioprinting of biomaterials. Chem Rev, 120: 10793–10833. https://doi.org/10.1021/acs.chemrev.0c00008 

101. Gudapati H, Dey M, Ozbolat I, 2016, A comprehensive review on droplet-based bioprinting: Past, present and future. Biomaterials, 102: 20–42. https://doi.org/10.1016/j.biomaterials.2016.06.012 

102. Mandrycky C, Wang Z, Kim K, et al., 2016, 3D bioprinting for engineering complex tissues. Biotechnol Adv, 34: 422–434. https://doi.org/10.1016/j.biotechadv.2015.12.011 

103. Xiang Y, Miller K, Guan J, et al., 2022, 3D bioprinting of complex tissues in vitro: State-of-the-art and future perspectives. Arch Toxicol, 96: 691–710. https://doi.org/10.1007/s00204-021-03212-y 

104. Ma X, Liu J, Zhu W, et al., 2018, 3D bioprinting of functional tissue models for personalized drug screening and in vitro disease modeling. Adv Drug Deliv Rev, 132: 235–251. https://doi.org/10.1016/j.addr.2018.06.011
 
105. Pati F, Gantelius J, Svahn HA, 2016, 3D bioprinting of tissue/ organ models. Angew Chem Int Ed Engl, 55: 4650–4665. https://doi.org/10.1002/anie.201505062 

106. Ng WL, Huang X, Shkolnikov V, et al., 2022, Controlling droplet impact velocity and droplet volume: Key factors to achieving high cell viability in sub-nanoliter droplet-based bioprinting. Int J Bioprint, 8: 424. https://doi.org/10.18063/ijb.v8i1.424 

107. Kacarevic ZP, Rider PM, Alkildani S, et al., 2018, An introduction to 3D bioprinting: Possibilities, challenges and future aspects. Materials (Basel), 11: 2199. https://doi.org/10.3390/ma11112199 

108. Gao D, Zhou JG, 2019, Designs and applications of electrohydrodynamic 3D printing. Int J Bioprint, 5: 172. https://doi.org/10.18063/ijb.v5i1.172 

109. Ng WL, Lee JM, Yeong WY, et al., 2017, Microvalve-based bioprinting-process, bio-inks and applications. Biomater Sci, 5: 632–647. https://doi.org/10.1039/c6bm00861e
 
110. Choi YJ, Park H, Ha DHi et al., 2021, 3D bioprinting of in vitro models using hydrogel-based bioinks. Polymers (Basel), 13: 366. https://doi.org/10.3390/polym13030366
 
111. Li W, Mille LS, Robledo JA, et al., 2020, Recent advances in formulating and processing biomaterial inks for vat polymerization-based 3D printing. Adv Healthc Mater, 9: e2000156. https://doi.org/10.1002/adhm.202000156
 
112. Ng WL, Lee JM, Zhou M, et al., 2020, Vat polymerization-based bioprinting-process, materials, applications and regulatory challenges. Biofabrication, 12: 022001. https://doi.org/10.1088/1758-5090/ab6034
 
113. Jing X, Fu H, Yu B, et al., 2022, Two-photon polymerization for 3D biomedical scaffolds: Overview and updates. Front Bioeng Biotechnol, 10: 994355. https://doi.org/10.3389/fbioe.2022.994355
 
114. Huang Z, Tsui G, Deng Y, et al., 2020, Two-photon polymerization nanolithography technology for fabrication of stimulus-responsive micro/nano-structures for biomedical applications. Nanotechnol Rev, 9: 1118–1136. https://doi.org/10.1515/ntrev-2020-0073 

115. Otuka AJ, Tomazio NB, Paula KT, et al., 2021, Two-photon polymerization: functionalized microstructures, micro-resonators, and bio-scaffolds. Polymers (Basel), 13: 1994. https://doi.org/10.3390/polym13121994 

116. Fransen MF, Addario G, Bouten CV, et al., 2021, Bioprinting of kidney in vitro models: Cells, biomaterials, and manufacturing techniques. Essays Biochem, 65: 587–602. https://doi.org/10.1042/EBC20200158 

117. Radi ZA, 2019, Kidney pathophysiology, toxicology, and  
drug-induced injury in drug development. Int J Toxicol, 38: 215–227. https://doi.org/10.1177/1091581819831701
 
118. Pregosin NC, Bronstein R, Mallipattu SK, 2021, Recent advances in kidney bioengineering. Front Pediatr, 9: 743301. https://doi.org/10.3389/fped.2021.743301 

119. Homan KA, Kolesky DB, Skylar-Scott MA, et al., 2016, Bioprinting of 3D convoluted renal proximal tubules on perfusable chips. Sci Rep, 6: 34845. https://doi.org/10.1038/srep34845 

120. Lin NY, Homan KA, Robinson SS, et al., 2019, Renal reabsorption in 3D vascularized proximal tubule models. Proc Natl Acad Sci U S A, 116: 5399–5404. https://doi.org/10.1073/pnas.1815208116 

121. Lawlor KT, Vanslambrouck JM, Higgins JW, et al., 2021, Cellular extrusion bioprinting improves kidney organoid reproducibility and conformation. Nat Mater, 20: 260–271. https://doi.org/10.1038/s41563-020-00853-9 

122. King SM, Higgins JW, Nino CR, et al., 2017, 3D proximal tubule tissues recapitulate key aspects of renal physiology to enable nephrotoxicity testing. Front Physiol, 8: 123. https://doi.org/10.3389/fphys.2017.00123 

123. Gao C, Lu C, Jian Z, et al., 2021, 3D bioprinting for fabricating artificial skin tissue. Colloids Surf B Biointerfaces, 208: 112041. https://doi.org/10.1016/j.colsurfb.2021.112041 

124. Weng T, Zhang W, Xia Y, et al., 2021, 3D bioprinting for skin tissue engineering: Current status and perspectives. J Tissue Eng, 12: 20417314211028574. https://doi.org/10.1177/20417314211028574 

125. Manita PG, Garcia-Orue I, Santos-Vizcaino E, et al., 2021, 3D Bioprinting of functional skin substitutes: From current achievements to future goals. Pharmaceuticals (Basel), 14: 362. https://doi.org/10.3390/ph14040362 

126. Ng WL, Wang S, Yeong WY, et al., 2016, Skin bioprinting: Impending reality or fantasy? Trends Biotechnol, 34: 689–699. https://doi.org/10.1016/j.tibtech.2016.04.006
 
127. Tarassoli SP, Jessop ZM, Al-Sabah A, et al., 2018, Skin tissue engineering using 3D bioprinting: An evolving research field. J Plast Reconstr Aesthet Surg, 71: 615–623. https://doi.org/10.1016/j.bjps.2017.12.006 

128. Abaci HE, Guo Z, Coffman A, et al., 2016, Human skin constructs with spatially controlled vasculature using primary and iPSC-derived endothelial cells. Adv Healthc Mater, 5: 1800–1807. https://doi.org/10.1002/adhm.201500936 

129. Min D, Lee W, Bae IH, et al., 2018, Bioprinting of biomimetic skin containing melanocytes. Exp Dermatol, 27: 453–459. https://doi.org/10.1111/exd.13376 

130. Ng WL, Qi JT, Yeong WY, et al., 2018, Proof-of-concept: 3D bioprinting of pigmented human skin constructs. Biofabrication, 10: 025005. https://doi.org/10.1088/1758-5090/aa9e1e 

131. Hong S, Song JM, 2021, A 3D cell printing-fabricated HepG2 liver spheroid model for high-content in situ quantification of drug-induced liver toxicity. Biomater Sci, 9: 5939–5950. https://doi.org/10.1039/d1bm00749a
 
132. Kizawa H, Nagao E, Shimamura M, et al., 2017, Scaffold-free 3D bio-printed human liver tissue stably maintains metabolic functions useful for drug discovery. Biochem Biophys Rep, 10: 186–191. https://doi.org/10.1016/j.bbrep.2017.04.004
 
133. Ma X, Qu X, Zhu W, et al., 2016, Deterministically patterned biomimetic human iPSC-derived hepatic model via rapid 3D bioprinting. Proc Natl Acad Sci U S A, 113: 2206–2211. https://doi.org/10.1073/pnas.1524510113 

134. Faulkner-Jones A, Fyfe C, Cornelissen DJ, et al., 2015, Bioprinting of human pluripotent stem cells and their directed differentiation into hepatocyte-like cells for the generation of mini-livers in 3D. Biofabrication, 7: 044102. https://doi.org/10.1088/1758-5090/7/4/044102 

135. Lei M, Wang X, 2016, Biodegradable polymers and stem cells for bioprinting. Molecules, 21: 539. https://doi.org/10.3390/molecules21050539
 
136. Poyck PP, Pless G, Hoekstra R, et al., 2007, In vitro comparison of two bioartificial liver support systems: MELS CellModule and AMC-BAL. Int J Artif Organs, 30: 183–191. https://doi.org/10.1177/039139880703000302

137. Calise F, Mancini A, Amoroso P, et al., 2001, Functional evaluation of the AMC-BAL to be employed in a multicentric clinical trial for acute liver failure. Transplant Proc, 33: 647–649. https://doi.org/10.1016/s0041-1345(00)02183-7 

138. Nibourg GA, Hoekstra R, van der Hoeven TV, et al., 2013, Effects of acute-liver-failure-plasma exposure on hepatic functionality of HepaRG-AMC-bioartificial liver. Liver Int, 33: 516–524. https://doi.org/10.1111/liv.12090 

139. van de Kerkhove MP, Poyck PP, van Wijk AC, et al., 2005, Assessment and improvement of liver specific function of the AMC-bioartificial liver. Int J Artif Organs, 28: 617–630. https://doi.org/10.1177/039139880502800611
 
140. van de Kerkhove MP, Poyck PP, Deurholt T, et al., 2005, Liver support therapy: an overview of the AMC-bioartificial liver research. Dig Surg, 22: 254–264. https://doi.org/10.1159/000088055 

141. Kammerer S, 2021, Three-dimensional liver culture systems to maintain primary hepatic properties for toxicological analysis in vitro. Int J Mol Sci, 22: 1024. https://doi.org/10.3390/ijms221910214
 
142. Algahtani MS, 2021, Assessment of pharmacist’s knowledge and perception toward 3D printing technology as a dispensing method for personalized medicine and the readiness for implementation. Pharmacy (Basel), 9: 68. https://doi.org/10.3390/pharmacy9010068 

143. Joseph JF, Gronbach L, Garcia-Miller J, et al., 2020, Automated real-time tumor pharmacokinetic profiling in 3D models: A novel approach for personalized medicine. Pharmaceutics, 12: 413. https://doi.org/10.3390/pharmaceutics12050413 

144. Turetta M, Ben FD, Brisotto G, et al., 2018, Emerging technologies for cancer research: Towards personalized medicine with microfluidic platforms and 3D tumor models. Curr Med Chem, 25: 4616–4637. https://doi.org/10.2174/0929867325666180605122633 

145. Liu Y, Chen YG, 2018, 2D-and 3D-based intestinal stem cell cultures for personalized medicine. Cells, 7: 225. https://doi.org/10.3390/cells7120225
 
146. Elcin YM, 2017, Special issue: Organs-on-chips & 3D-Bioprinting technologies for personalized medicine. Stem Cell Rev Rep, 13: 319–320. https://doi.org/10.1007/s12015-017-9744-2